Showing 2071-2080 of 3201 results for "".
Tinea Incognito, the Great Imitator: Case Reports
https://practicaldermatology.com/youngmd-connect/resident-resource-center/tinea-incognito-the-great-imitator-case-reports/23925/What’s New in Topical Treatment for Actinic Keratosis?
https://practicaldermatology.com/topics/skin-cancer-photoprotection/whats-new-in-topical-treatment-for-actinic-keratosis/23483/An overview of the latest developments in treatment of these common precancerous lesions.Topical Treatment Options for Hyperhidrosis
https://practicaldermatology.com/youngmd-connect/resident-resource-center/topical-treatment-options-for-hyperhidrosis/23340/A review of topical therapies for primary focal hyperhidrosisTriple Threat
https://practicaldermatology.com/topics/general-topics/triple-threat/20629/In defense of the Aron Regimen for resistant atopic dermatitis.GLP-1 Receptor Agonists and the Aesthetic Patient: Considerations for the Dermatologist
https://practicaldermatology.com/issues/novemberdecember-2025/glp-1-receptor-agonists-and-the-aesthetic-patient/48900/The impact of glucagon-like peptide-1 agonists (GLP-1), such as semaglutide, tirzepatide and liraglutide, has transformed the healthcare industry and, in particular, aesthetic dermatology. The most common intended use of these medications, namely diabetes management and weight loss, can lead to a muTargeting the OX40 Pathway
https://practicaldermatology.com/issues/october-2025/targeting-the-ox40-pathway/39764/A Promising New Avenue in Atopic DermatitisComorbidities in Atopic Dermatitis
https://practicaldermatology.com/issues/october-2025/comorbidities-in-atopic-dermatitis/39756/In this article, as part of a series on comorbidities associated with immune-mediated skin diseases, we explore the spectrum of comorbidities linked to AD.Staphylococcus aureus Colonization
https://practicaldermatology.com/issues/september-2025/staphylococcus-aureus-colonization/37626/In a recent review article, Piewngam and Otto examined the epidemiology, mechanisms, and clinical implications of Staphylococcus aureus (S. aureus) colonization, while evaluating both current and emerging strategies for decolonization.In The Pipeline: Phase 1, 2, and 3
https://practicaldermatology.com/programs/practical-dermatology-focus-psoriasis/pipeline-phase-1-2-and-3/29087/This summary provides the latest news on of some of the recent Phase 1, Phase 2, and Phase 3 clinical studies for psoriasis treatments.Annual Trends in Medicare Part D Prescription Claims for Guselkumab, 2018–2020
https://practicaldermatology.com/programs/practical-dermatology-focus-psoriasis/annual-trends-in-medicare-part-d-prescription-claims-for-guselkumab-20182020/28861/Jachin Wu, MD, FAAD, and colleagues talk about Medicare claims for guselkumab